Nicotinamide adenine dinucleotide (NAD⁺) sits at the intersection of energy metabolism, DNA repair, and stress signaling in the brain. This article examines the research question of whether measurable NAD⁺ deficiency is mechanistically implicated in how neurodegenerative disease progresses, or whether it merely reflects tissue that is already being lost.

Why NAD⁺ matters in the aging brain

NAD⁺ is a redox cofactor and signaling substrate present in every cell, but the brain is unusually dependent on it. Neurons are among the most energy-demanding cells in the body, and they rely on a continuous supply of NAD⁺ to sustain glycolysis, the tricarboxylic acid cycle, and oxidative phosphorylation. According to a comprehensive review in Cell Metabolism, intracellular NAD⁺ levels fall with age across multiple tissues, and this decline is closely linked to the cellular hallmarks of brain aging and neurodegenerative disorders.¹

Importantly, the decline is not uniform. A 2024 analysis of NAD⁺ metabolism in brain cells reports that NAD⁺ biosynthesis and degradation differ substantially between neurons, astrocytes, microglia, and endothelial cells, producing region-specific depletion patterns associated with the selective neuronal vulnerability observed in disease.² This distinction matters for the central research question: a factor that tracks tightly with which cells are lost, and in what order, behaves more like a participating mechanism than a downstream readout of damage already done.

The broader context is the well-documented decline of brain energy metabolism with age. Reviews of aging-brain bioenergetics describe reduced glucose utilization and mitochondrial efficiency as early features that precede overt pathology, framing metabolic decline as part of the pathogenesis rather than a late consequence.¹⁰ Because NAD⁺ availability governs the flux capacity of those metabolic pathways, its erosion is one plausible node where a general energetic problem becomes a selective, disease-relevant one.

How NAD⁺ decline disrupts mitochondrial bioenergetics

NAD⁺ and its reduced form NADH act as the primary electron shuttle for the mitochondrial electron transport chain. When the cytosolic and mitochondrial NAD⁺ pools contract, the efficiency of oxidative phosphorylation falls, electron leak and reactive oxygen species rise, and mitochondrial DNA becomes more exposed to oxidative damage. The Cell Metabolism review describes this as a self-reinforcing loop in which reduced NAD⁺ compromises respiration, and impaired respiration further limits the cell's capacity to regenerate NAD⁺.¹

Beyond its role as a redox carrier, NAD⁺ is the obligatory substrate for the sirtuin family of deacylases. SIRT1 and SIRT3, in particular, coordinate mitochondrial biogenesis, antioxidant defense, and metabolic adaptation. When NAD⁺ is scarce, sirtuin activity is constrained, weakening the transcriptional programs that would normally expand mitochondrial mass and reinforce stress resistance. Reviews of mitochondria-targeted neuroprotection identify this NAD⁺–sirtuin–mitochondrial axis as a recurring theme across neurodegenerative models, where restoring mitochondrial competence is a persistent experimental goal rather than an established clinical outcome.¹³ Research into mitochondrial-derived signaling peptides such as MOTS-C reflects the same underlying interest in how metabolic cofactors and mitochondrial state are coupled.

Genomic maintenance: PARP1, DNA damage, and sirtuins

The nucleus imposes its own demand on the NAD⁺ pool. Poly(ADP-ribose) polymerase 1 (PARP1) is activated by DNA strand breaks and consumes NAD⁺ to build poly(ADP-ribose) chains that recruit repair machinery. In moderation this is protective. Under conditions of sustained genotoxic stress, however, PARP1 hyperactivation can drain cellular NAD⁺ faster than salvage pathways replenish it, producing an energetic crisis that couples DNA damage directly to metabolic collapse.¹⁴

This creates a competition. Both PARP enzymes and sirtuins depend on the same limited NAD⁺ supply, so heavy PARP1 activity can indirectly suppress sirtuin-mediated maintenance of the genome and mitochondria. The result is a networked failure rather than an isolated defect: reduced DNA-repair fidelity, altered stress-response gene expression, and diminished mitochondrial upkeep reinforce one another.

The vascular dimension

NAD⁺-dependent processes also extend to the neurovascular interface. In a 2023 Neuron study, aging-induced blood–brain barrier damage in mice was linked to a CX43–PARP1 axis, and NAD⁺ repletion mitigated the barrier dysfunction in that model.⁸ This illustrates that NAD⁺ biology in the brain is not confined to neurons; endothelial and glial compartments participate, consistent with the cell-type specificity reported elsewhere.²

The NAD⁺ consumers that drive depletion

A central shift in recent literature is the recognition that NAD⁺ decline is not only a matter of reduced synthesis but of increased consumption. Three enzyme systems are repeatedly implicated.

CD38 is an ecto-enzyme expressed on immune and glial cells whose expression rises with age. A 2020 Nature Metabolism study reported that age-associated CD38 induction in immune cells regulates tissue NAD⁺ and NMN levels, positioning inflammation-linked NAD⁺ consumption as a driver of the age-related decline.⁶ Reviews of CD38 pharmacology have since framed the enzyme as an emerging target in diseases of aging precisely because of this NADase activity.⁷

SARM1 provides perhaps the clearest mechanistic link between NAD⁺ metabolism and neuronal structure. Work in Neuron demonstrated that SARM1 functions as a metabolic sensor: it is activated by an increased ratio of NMN to NAD⁺, and once active its own NADase activity accelerates axonal NAD⁺ loss to trigger axon degeneration.⁴ Companion reviews describe SARM1 as the central executioner of an intrinsic axon-destruction program governed by the NAD⁺ metabolome, relevant to a range of neuropathies and neurodegenerative conditions.⁵¹² The implication is direct: in these models NAD⁺ disruption is not a symptom of degeneration but part of its molecular trigger.

Proteostasis and the mitochondrial unfolded protein response

NAD⁺ availability also intersects with how cells manage misfolded proteins inside mitochondria. The mitochondrial unfolded protein response (UPRᵐᵗ) is a transcriptional stress program that upregulates chaperones and proteases when mitochondrial proteostasis is threatened. A 2025 study in Advanced Science using rotenone- and MPTP-based Parkinson's disease models reported that NAD⁺ boosters such as NMN increased UPRᵐᵗ- and mitophagy-related quality control, reduced pro-inflammatory cytokine expression, and, in mice, attenuated motor deficits through an ATF4-related mitochondrial UPR pathway.³

These findings position NAD⁺ as a regulatory node within mitochondrial stress adaptation rather than a standalone intervention. They also carry an important caveat that the authors themselves emphasize: the work is conducted in cross-species disease models, and the presence of a mechanistic effect in rodents does not establish a therapeutic effect in people. The value of such studies lies in clarifying how NAD⁺ deficiency could contribute to proteostatic failure, not in demonstrating a clinical benefit.

What preclinical and early human studies actually show

The honest summary is that the mechanistic case is strong and the translational case is thin. Rodent and cellular models consistently show that manipulating NAD⁺ precursor levels can shift disease-associated molecular phenotypes — mitochondrial dynamics, inflammatory signaling, DNA-repair capacity, and axonal survival.¹³ These reports describe changes in molecular and cellular markers rather than definitive functional recovery, and outcomes depend heavily on disease context, timing, and cell type.

Human data remain preliminary. In one randomized, double-blinded, placebo-controlled phase-II trial, a combined metabolic activator formulation was associated with improved cognitive scores in Alzheimer's disease patients; however, that formulation bundled several metabolic substrates together, so it does not isolate an NAD⁺-specific effect, and a single phase-II result is not a basis for general conclusions.⁹ Analyses of Parkinson's disease and aging further stress that separating cause from consequence is genuinely difficult, because metabolic decline, mitochondrial dysfunction, and neuronal loss co-occur and reinforce one another.¹¹

None of the NAD⁺-related compounds discussed here is an approved treatment for any neurodegenerative disease as of 2026. Findings from rodent studies cannot be extrapolated directly to humans given species-specific differences in NAD⁺ metabolism, and interpreting the literature responsibly means holding the mechanistic plausibility and the clinical uncertainty at the same time.

Why NAD⁺ deficiency is a systems-level contributor

Taken together, the evidence supports a specific framing: NAD⁺ deficiency is best understood as a convergence point rather than a single cause. It integrates several failure modes into one cellular stress axis.

• Metabolic coordination. Disrupted redox balance and impaired oxidative phosphorylation reduce cellular resilience.¹
• Genomic maintenance. Competition between PARP1 and sirtuins for a shrinking NAD⁺ pool weakens DNA repair and stress-response transcription.¹⁴
• Mitochondrial signaling. Reduced NAD⁺ constrains biogenesis, mitophagy, and the UPRᵐᵗ, compromising adaptation to injury.³
• Cell-type specificity. Neurons, astrocytes, microglia, and endothelial cells show distinct NAD⁺-dependent responses, shaping which populations become vulnerable.²⁸

This systems-level view explains why NAD⁺ depletion reshapes intercellular metabolic coupling and stress-communication networks, and why it correlates so tightly with selective vulnerability. It also explains why the field remains cautious: a node embedded in this many pathways is mechanistically compelling but experimentally hard to isolate, which is exactly why reproducible, well-characterized reagents matter for the research that will eventually resolve these questions.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.